Recent advances in the molecular pathogenesis of Ewing's sarcoma
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Tumor development is a complex process resulting from interplay between mutations in oncogenes and tumor suppressors, host susceptibility factors, and cellular context. Great advances have been made by studying rare tumors with unique clinical, genetic, or molecular features. Ewing's sarcoma serves as an excellent paradigm for understanding tumorigenesis because it exhibits some very useful and important characteristics. For example, nearly all cases of Ewing's sarcoma contain the (11;22)(q24;q12) chromosomal translocation that encodes the EWS/FLI oncoprotein. Besides the t(11;22), however, many cases have otherwise simple karyotypes with no other demonstrable abnormalities. Furthermore, it seems that an underlying genetic susceptibility to Ewing's sarcoma, if it exists, must be rare. These two features suggest that EWS/FLI is the primary mutation that drives the development of this tumor. Finally, Ewing's sarcoma is an aggressive tumor that requires aggressive treatment. Thus, improved understanding of the pathogenesis of this tumor will not only be of academic interest, but may also lead to new therapeutic approaches for individuals afflicted with this disease. The purpose of this review is to highlight recent advances in understanding the molecular pathogenesis of Ewing's sarcoma, while considering the questions surrounding this disease that still remain and how this knowledge may be applied to developing new treatments for patients with this highly aggressive disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours
Delattre, O., Zucman, J., Plougastel, B., Desmaze, C., Melot, T., Peter, M., Kovar, H., Joubert, I., de Jong, P., Rouleau, G., et al. (1992) · Nature · doi:10.1038/359162a0 · Cited by 1,907 · cited 2×
“In the context of this fusion, a strong transcriptional activation domain is contributed by EWS and an ETS-type DNA-binding domain is contributed by FLI (Delattre et al., 1992; May et al., 1993a, b; Lessnick et al., 1995).”
BackgroundThe ETS-domain transcription factor family
Sharrocks, A. D. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35099076 · Cited by 1,086 · cited 5×
“May WA, Arvand A, Thompson AD, Braun BS, Wright M, Denny CT. (1997). EWS/FLI1-induced manic fringe renders NIH 3T3 cells tumorigenic.”
BackgroundInfluentialCommon Musculoskeletal Tumors of Childhood and Adolescence
Arndt, C. A. S., & Crist, W. M. (1999) · New England Journal of Medicine · doi:10.1056/nejm199907293410507 · Cited by 657 · cited 1×
“Ewing’s sarcoma is a rare but important solid tumor in children and young adults (Arndt and Crist, 1999).”
BackgroundMay, W. A., Lessnick, S. L., Braun, B. S., Klemsz, M., Lewis, B. C., Lunsford, L. B., Hromas, R., & Denny, C. T. (1993) · Molecular and Cellular Biology · doi:10.1128/mcb.13.12.7393 · Cited by 497
Self-citationMicrosatellites as EWS/FLI response elements in Ewing's sarcoma
Gangwal, K., Sankar, S., Hollenhorst, P. C., Kinsey, M., Haroldsen, S. C., Shah, A. A., Boucher, K. M., Watkins, W. S., Jorde, L. B., Graves, B. J., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0801073105 · Cited by 297 · cited 5×
“The CAV1 promoter contains a GGAA microsatellite that is occupied by EWS/FLI in vivo (Gangwal et al., 2008), is highly expressed in Ewing’s sarcoma tumors, and promotes tumor growth in mouse xenograft models of Ewing’s sarcoma (Tirado et al., 2006).”
BackgroundInfluentialSelf-citationLinabery, A. M., & Ross, J. A. (2008) · Cancer · doi:10.1002/cncr.23866 · Cited by 246 · cited 1×
“This propensity to spread contributes to the poor prognosis for Ewing’s sarcoma patients and long-term cure rate of B60% (Linabery and Ross, 2008).”
BackgroundGuillon, N., Tirode, F., Boeva, V., Zynovyev, A., Barillot, E., & Delattre, O. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004932 · Cited by 218 · cited 1×
“This result was confirmed by a ChIP-sequencing approach as well (Guillon et al., 2009).”
ResultThe FLI-1 and chimeric EWS-FLI-1 oncoproteins display similar DNA binding specificities.
Mao, X., Miesfeldt, S., Yang, H., Leiden, J. M., & Thompson, C. B. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)32437-7 · Cited by 132
Szymczyna, B. R., & Arrowsmith, C. H. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m004294200 · Cited by 99 · cited 1×
“ETS family members (including EWS/FLI) bind to sequences containing a GGAA ‘core’ motif surrounded by bases that provide affinity and specificity to the interaction (Szymczyna and Arrowsmith, 2000; Sharrocks, 2001; Seth and Watson, 2005).”
BackgroundLuo, W., Gangwal, K., Sankar, S., Boucher, K. M., Thomas, D., & Lessnick, S. L. (2009) · Oncogene · doi:10.1038/onc.2009.262 · Cited by 93 · cited 1×
“Recently, GSTM4 was identified as a GGAAmicrosatellite-containing gene that was required for the transformed phenotype and modulates resistance to chemotherapeutic agents in Ewing’s sarcoma cells (Luo et al., 2009).”
BackgroundSelf-citation
Cited by
Grünewald, T. G. P., Cidre-Aranaz, F., Surdez, D., Tomazou, E. M., de Álava, E., Kovar, H., Sorensen, P. H., Delattre, O., & Dirksen, U. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0003-x · Cited by 873
A new subtype of bone sarcoma defined by BCOR-CCNB3 gene fusion
Pierron, G., Tirode, F., Lucchesi, C., Reynaud, S., Ballet, S., Cohen-Gogo, S., Perrin, V., Coindre, J.-M., & Delattre, O. (2012) · Nature Genetics · doi:10.1038/ng.1107 · Cited by 478
Children's Oncology Group's 2013 blueprint for research: Bone tumors
Gorlick, R., Janeway, K., Lessnick, S., Randall, R. L., Marina, N., & on behalf of the COG Bone Tumor Committee (2013) · Pediatric Blood & Cancer · doi:10.1002/pbc.24429 · Cited by 226
Self-citationGamie, Z., Kapriniotis, K., Papanikolaou, D., Haagensen, E., Da Conceicao Ribeiro, R., Dalgarno, K., Krippner-Heidenreich, A., Gerrand, C., Tsiridis, E., & Rankin, K. S. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.08.036 · Cited by 44
Metadata
- Authors
- Toomey, E. C., Schiffman, J. D., & Lessnick, S. L.
- Venue
- Oncogene
- Published
- 2010-06-14
- Volume
- 29
- Issue
- 32
- Pages
- 4504-4516
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W1996375162
- Cited by
- 191
- References
- 11
- FWCI
- 15.74
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.